alprenolol has been researched along with carvedilol in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Gaillard, P; Schambel, P; Testa, B | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Baker, JG | 1 |
| Carrupt, PA; Guillarme, D; Henchoz, Y; Rudaz, S; Veuthey, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Bard, B; Carrupt, PA; Martel, S | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Bond, RA; Callaerts-Vegh, Z; Evans, KL; Liu, X | 1 |
| Bond, RA; Callaerts-Vegh, Z; Cuba, DL; Davies, PJ; Evans, KL; Giles, H; Gurji, HA; Shipley, GL | 1 |
| Chen, J; Kim, IM; Rockman, HA; Salazar, NC; Tilley, DG; Violin, JD; Whalen, EJ | 1 |
| Pisklak, DM; Wawer, I; Zielińska-Pisklak, MA | 1 |
| Huang, B; Li, HH; Li, YX; Liu, X; Ma, L; Tao, YZ | 1 |
| Bond, RA; Bouvier, M; Forkuo, GS; Joshi, R; Knoll, BJ; Leff, P; Parra, S; Thanawala, VJ; Valdez, DJ | 1 |
| Andresen, BT; Chang, A; Chen, S; Cleveland, KH; Guo, L; Huang, KM; Huang, Y; Liang, S | 1 |
18 other study(ies) available for alprenolol and carvedilol
| Article | Year |
|---|---|
Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models.
Topics: Indoles; Ligands; Models, Molecular; Molecular Conformation; Molecular Structure; Piperazines; Propanolamines; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin; Structure-Activity Relationship; Tetrahydronaphthalenes | 1996 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Algorithms; Animals; Cell Line; CHO Cells; Cricetinae; Dioxoles; Humans; Propanolamines; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Receptors, Adrenergic, beta-3 | 2005 |
High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.
Topics: Chemical Phenomena; Chemistry, Pharmaceutical; Chemistry, Physical; Chromatography, Liquid; Mathematics; Pharmaceutical Preparations; Software | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
Topics: Chemistry, Pharmaceutical; Chromatography; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Pharmaceutical Preparations; Solubility; Technology, Pharmaceutical | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Chronic infusion of beta-adrenoceptor antagonist and inverse agonists decreases elevated protein kinase A activity in transgenic mice with cardiac-specific overexpression of human beta 2-adrenoceptor.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Alprenolol; Animals; Carbazoles; Carvedilol; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Heart Atria; Heart Ventricles; Humans; Infusion Pumps, Implantable; Mice; Mice, Transgenic; Myocardium; Propanolamines; Receptors, Adrenergic, beta-2 | 2002 |
Effects of different beta adrenoceptor ligands in mice with permanent occlusion of the left anterior descending coronary artery.
Topics: Adrenergic beta-Antagonists; Alprenolol; Animals; Carbazoles; Carvedilol; Coronary Disease; Coronary Vessels; Ligands; Male; Mice; Mice, Inbred C57BL; Propanolamines; Receptors, Adrenergic, beta | 2003 |
Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation.
Topics: Adrenergic beta-Antagonists; Alprenolol; Animals; Arrestins; beta-Arrestins; Carbazoles; Carvedilol; Cell Line, Transformed; Dose-Response Relationship, Drug; Enzyme Activation; Enzymes; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Heart; Humans; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Propanolamines; Quinazolines; Signal Transduction; Transcriptional Activation | 2008 |
1H and 13C NMR characteristics of β-blockers.
Topics: Acebutolol; Acids; Adrenergic beta-Antagonists; Alkalies; Alprenolol; Atenolol; Carbazoles; Carbon Isotopes; Carvedilol; Nuclear Magnetic Resonance, Biomolecular; Pindolol; Propanolamines; Propranolol; Protons; Timolol | 2011 |
β-Arrestin-biased signaling mediates memory reconsolidation.
Topics: Alprenolol; Animals; Arrestins; beta-Arrestin 2; beta-Arrestins; Brain; Brain Mapping; Carbazoles; Carvedilol; Cocaine; Cyclic AMP-Dependent Protein Kinases; Extracellular Signal-Regulated MAP Kinases; Male; Maze Learning; Memory; Mice; Mice, Inbred C57BL; Mice, Knockout; Phosphorylation; Propanolamines; Propranolol; Receptors, Adrenergic, beta-1; Signal Transduction; Time Factors | 2015 |
β-Blockers have differential effects on the murine asthma phenotype.
Topics: Adrenergic beta-Antagonists; Allergens; Alprenolol; Animals; Asthma; Bronchoalveolar Lavage Fluid; Carbazoles; Carvedilol; Cell Count; Epinephrine; Female; Male; Mice, Knockout; Models, Biological; Mucins; Nadolol; Ovalbumin; Phenotype; Propanolamines; Propranolol | 2015 |
Carvedilol inhibits EGF-mediated JB6 P+ colony formation through a mechanism independent of adrenoceptors.
Topics: Adrenergic beta-Antagonists; Alprenolol; Animals; Carvedilol; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; Epidermal Growth Factor; Inhibitory Concentration 50; Labetalol; Ligands; Mice; Mice, Inbred C57BL; Receptors, Adrenergic; Receptors, Adrenergic, beta; RNA, Small Interfering; Signal Transduction; Skin; Skin Neoplasms; Ultraviolet Rays | 2019 |